Hanna Cho

Hanna brings over 20 years of drug discovery and development and regulatory strategy experience to Biomea Fusion. Prior to joining Biomea, Hanna worked as a global regulatory lead at various biopharma companies including BioMarin, Iovance, Clovis Oncology, and Genentech. She successfully led cross-functional global teams for various products including approvals of vosoritide (first and only therapy for achondroplasia, the most common form of dwarfism) and rucaparib (for ovarian cancer with germline and somatic BRCA mutations diagnosed by a companion diagnostic). Hanna has diverse experiences in various functions of regulatory affairs including clinical/nonclinical, CMC, labeling, and international regulatory. Also, her regulatory strategy experience extends from pre-clinical to post-market life cycle management. Prior to switching her career to regulatory affairs, Hanna was a medicinal chemist at Plexxikon (acquired by Daiichi Sankyo) and Pharmacia (acquired by Pfizer).

As a medicinal chemist, Hanna designed and synthesized the active moiety of vemurafenib (the first personalized/precision medicine targeting melanoma) that is globally marketed as Zelboraf®, and it is considered the first drug designed using fragment-based lead discovery to be approved and marketed.

Hanna earned her Ph.D. in medicinal organic chemistry from the University of Illinois at Chicago.